Low expression of miR-1469 predicts disease progression and unfavorable post‑surgical clinical outcomes in patients with esophageal squamous cell cancer

Liu,Jin; Wang,Chuifang; Liu,Xiangyan; Wang,Yu; Liu,Haibo; Ren,Guohua; Zhu,Liangming; Sun,Zhigang; Chen,Zhitao

doi:10.3892/ol.2017.5957

Low expression of miR-1469 predicts disease progression and unfavorable post‑surgical clinical outcomes in patients with esophageal squamous cell cancer

Authors:
- Jin Liu
- Chuifang Wang
- Xiangyan Liu
- Yu Wang
- Haibo Liu
- Guohua Ren
- Liangming Zhu
- Zhigang Sun
- Zhitao Chen
View Affiliations

Affiliations: Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Thoracic Surgery, Liaocheng Tumor Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Gastroenterology, Zhangqiu People's Hospital, Zhangqiu, Shandong 250200, P.R. China, Department of Thoracic Surgery, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China, Department of Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, P.R. China
Published online on: March 30, 2017 https://doi.org/10.3892/ol.2017.5957
Pages: 4469-4474

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have demonstrated that deregulated microRNA (miRNA/miR) expression has a profound impact on biological and pathological processes; abnormal miR-1469 expression was detected in several human malignancies. In the present study, the clinicopathological and prognostic significance of miR‑1469 was assessed in 129 patients with esophageal squamous cell cancer (ESCC) who successfully underwent esophagectomy and esophagogastrostomy. Low miR‑1469 expression was identified to be significantly associated with tumor invasion depth (P=0.026), lymph node metastasis status (P<0.001) and pathological tumor stage (P<0.001). Survival analysis demonstrated that patients with low miR‑1469 expression had significantly poorer disease‑free survival (DFS) (18.2 vs. 43.2%; P=0.004) and overall survival (29.1 vs. 47.3%; P=0.029) 5 years following surgery compared with patients with high miR‑1469 expression. Univariate survival analysis demonstrated that low miR‑1469 expression significantly predicted unfavorable 5‑year DFS among patients with N1‑3 disease (7.1 vs. 31.8%; P=0.043). The results from the present study indicate that miR‑1469 expression could be used in the clinic to predict ESCC progression and prognosis. This will aid in the identification of high‑risk patients with ESCC that require more aggressive therapeutic interventions.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X and He J: Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 5:19–26. 2013.PubMed/NCBI
3	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB and Hochwald SN: Esophageal cancer-the five year survivors. J Surg Oncol. 103:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hong L, Han Y, Zhang H and Fan D: Prognostic markers in esophageal cancer: From basic research to clinical use. Expert Rev Gastroenterol Hepatol. 9:887–889. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
7	Naidu S, Magee P and Garofalo M: MiRNA-based therapeutic intervention of cancer. J Hematol Oncol. 8:682015. View Article : Google Scholar : PubMed/NCBI
8	Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
9	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
10	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
11	Ohtsuka M, Ling H, Doki Y, Mori M and Calin GA: MicroRNA processing and human cancer. J Clin Med. 4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
12	Fix LN, Shah M, Efferth T, Farwell MA and Zhang B: MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60. Cancer Genomics Proteomics. 7:261–277. 2010.PubMed/NCBI
13	White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, et al: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yang B, Jing C, Wang J, Guo X, Chen Y, Xu R, Peng L, Liu J and Li L: Identification of microRNAs associated with lymphangiogenesis in human gastric cancer. Clin Transl Oncol. 16:374–379. 2014. View Article : Google Scholar : PubMed/NCBI
15	Xu C, Zhang L, Li H, Liu Z, Duan L and Lu C: MiRNA-1469 promotes lung cancer cells apoptosis through targeting STAT5a. Am J Cancer Res. 5:1180–1189. 2015.PubMed/NCBI
16	Hamilton SR and Aaltonen LA: Pathology and genetics of tumours of the digestive system, World Health Organization classification of tumours. IARC Press; Lyon: pp. 10–25. 2000
17	Edge SF, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: Esophagus and esophagogastric junctionAJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: pp. 103–111. 2010
18	Zhou H, Tang K, Xiao H, Zeng J, Guan W, Guo X, Xu H and Ye Z: A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res. 34:532015. View Article : Google Scholar : PubMed/NCBI
19	Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, et al: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res. 15:6192–6200. 2009. View Article : Google Scholar : PubMed/NCBI
20	Enzinger PC and Mayer RJ: Esophageal Cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
21	Li SH, Tian H, Yue WM, Li L, Gao C, Li WJ, Hu WS and Hao B: Metastasis-associated protein 1 nuclear expression is closely associated with tumor progression and angiogenesis in patients with esophageal squamous cell cancer. World J Surg. 36:623–631. 2012. View Article : Google Scholar : PubMed/NCBI
22	Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
23	Pipan V, Zorc M and Kunej T: MicroRNA polymorphisms in cancer: A literature analysis. Cancers (Basel). 7:1806–1814. 2015. View Article : Google Scholar : PubMed/NCBI
24	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
25	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
26	Garzon R, Calin GA and Croce CM: MicroRNAs in Cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
27	Raza U, Zhang JD and Sahin O: MicroRNAs: Master regulators of drug resistance, stemness, and metastasis. J Mol Med (Berl). 92:321–336. 2014. View Article : Google Scholar : PubMed/NCBI
28	Tricoli JV and Jacobson JW: MicroRNA: Potential for cancer detection, diagnosis, and prognosis. Cancer Res. 67:4553–4555. 2007. View Article : Google Scholar : PubMed/NCBI
29	Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010. View Article : Google Scholar : PubMed/NCBI
30	Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA and Wu X: Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila). 1:460–469. 2008. View Article : Google Scholar : PubMed/NCBI